Clarivate (NYSE: CLVT - Get Free Report) and 3 E Network Technology Group (NASDAQ: MASK - Get Free Report) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends. Valuation and Earnings
Shares of Clarivate PLC (NYSE: CLVT - Get Free Report) have been assigned a consensus recommendation of "Reduce" from the eight research firms that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation and five have issued a hold recommendation on the company. The average 1 year price
LONDON, March 26, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the Clarivate AI50, a new data-driven benchmark of organizations demonstrating exceptional leadership in high-impact artificial intelligence (AI) inventions. Following our announcement of the Top 100 Global Innovators 2026, this report dives deeper into the AI world, where organizations such as NVIDIA, Micron Technology, Alphabet, Qualcomm or Foxconn are creating foundational capability in AI, translating AI into complex systems, and scaling into products, workflows and industrial environments.
Most investors have never heard of Clarivate. The company operates largely outside mainstream investor attention.
Clarivate Plc (CLVT) Presents at Wolfe Research FinTech Forum Transcript
Advancing Clarivate strategy to extend proprietary intelligence into enterprise AI ecosystems Bringing Clarivate domain-specific regulatory insights into Claude to support life sciences workflows LONDON, March 10, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced they will integrate Clarivate's proprietary regulatory intelligence with Claude's AI reasoning capabilities. The collaboration gives biopharma, biotech, medtech and clinical research organizations intelligent, context-aware access to authoritative regulatory data within the AI workflows they already use.
Clarivate is executing a turnaround, with management focusing on debt reduction, divestitures, and share buybacks after years of value-destructive acquisitions. Q4 and FY25 results marked the first time CLVT met initial full-year guidance since 2019, with sequential organic ACV growth and 88% recurring revenue. 2026 guidance projects organic ACV growth of 2–3%, adjusted EBITDA margin near 43%, and FCF around $400M, despite headline revenue decline from low-margin business exits.
Clarivate (CLVT) remains a hold as core organic growth continues to deteriorate, with no evidence of recovery despite multiple compression. AI-driven shifts in user behavior and low barriers to entry are intensifying competitive threats, raising doubts about CLVT's long-term growth prospects. Strategic positives include the planned sale of the underperforming LSH segment and improved recurring revenue mix, but these do not offset weak fundamentals.
Clarivate PLC (NYSE: CLVT - Get Free Report) was the target of a large growth in short interest in February. As of February 13th, there was short interest totaling 61,217,098 shares, a growth of 21.2% from the January 29th total of 50,498,661 shares. Based on an average daily volume of 9,542,428 shares, the days-to-cover ratio is
Shares of Clarivate PLC (NYSE: CLVT - Get Free Report) have received a consensus rating of "Reduce" from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell rating and five have issued a hold rating on the company. The average 12-month price objective
